{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:25:02Z","timestamp":1775244302760,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01100","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T04:56:08Z","timestamp":1569300968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The Top 100 Highly Cited Original Articles on Immunotherapy for Childhood Leukemia"],"prefix":"10.3389","volume":"10","author":[{"given":"Qing","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Hui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.biopha.2017.10.100","article-title":"Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy","volume":"97","author":"Acheampong","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/leu.2016.391","article-title":"Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors","volume":"31","author":"Aldoss","year":"2017","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ctrv.2018.07.005","article-title":"Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia","volume":"69","author":"Bosshard","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"B5","volume-title":"Sources of information on specific subjects","author":"Bradford","year":"1985"},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1001\/jama.287.21.2847","article-title":"Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals","volume":"287","author":"Callaham","year":"2002","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1523-1739.2010.01509.x","article-title":"Patterns of citations of open access and non-open access conservation biology journal papers and book chapters","volume":"24","author":"Calver","year":"2010","journal-title":"Conserv. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/mpo.1303","article-title":"Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study","volume":"38","author":"Dagher","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis and Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-017-0519-7","article-title":"Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia","volume":"10","author":"Fan","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MOP.0000000000000572","article-title":"New developments in immunotherapy for pediatric leukemia","volume":"30","author":"Foster","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrc.2016.3","article-title":"Leukaemia \u2018firsts\u2019 in cancer research and treatment","volume":"16","author":"Greaves","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2018.211011","article-title":"The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models","volume":"104","author":"Hicks","year":"2019","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1002\/cncr.32139","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","article-title":"CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells","volume":"6","author":"Jitschin","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell\u2013induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.blre.2017.08.001","article-title":"Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine","volume":"31","author":"Lam","year":"2017","journal-title":"Blood Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ejh.13247","article-title":"Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry","volume":"103","author":"Lennmyr","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, a potent CD123-directed antibody-drug conjugate for acute myeloid leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.ijcard.2016.08.002","article-title":"The most cited articles in coronary heart disease: a bibliometric analysis between 1970 and 2015","volume":"222","author":"Liao","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-019-0703-z","article-title":"Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","author":"Majzner","year":"2017","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12094-016-1531-z","article-title":"Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007","volume":"19","author":"Marcos-Gragera","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3324\/haematol.2016.158485","article-title":"Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia","volume":"102","author":"McGinn","year":"2017","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","article-title":"Epidemiological patterns of leukaemia in 184 countries: a population-based study","volume":"5","author":"Miranda-Filho","year":"2018","journal-title":"Lancet Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41422-019-0162-7","article-title":"Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy","volume":"29","author":"Mugoni","year":"2019","journal-title":"Cell Res."},{"key":"B36","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume-title":"Leukemia","author":"Pan","year":"2019"},{"key":"B37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa035091","article-title":"Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia","volume":"349","author":"Pui","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41235-017-0049-4","article-title":"The importance of search strategy for finding targets in open terrain","volume":"2","author":"Riggs","year":"2017","journal-title":"Cogn. Res. Princ. Implic."},{"key":"B41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/mpo.10240","article-title":"Treatment of Ewing sarcoma family of tumors: current status and outlook for the future","volume":"40","author":"Rodriguez-Galindo","year":"2003","journal-title":"Med. Pediatr. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/sj.leu.2402988","article-title":"WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies","volume":"17","author":"Rosenfeld","year":"2003","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","article-title":"Emerging therapies for acute myeloid leukemia","volume":"10","author":"Saygin","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1182\/blood-2012-01-401349","article-title":"Radiation therapy for the management of patients with HTLV-1\u2013associated adult T-cell leukemia\/lymphoma","volume":"120","author":"Simone","year":"2012","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing oF CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF02981935","article-title":"Wilms\u2019 tumor gene WT1: its oncogenic function and clinical application","volume":"73","author":"Sugiyama","year":"2001","journal-title":"Int. J. Hematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fphar.2019.00108","article-title":"The top-100 highly cited original articles on drug therapy for ventilator-associated pneumonia","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR\u2013T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.blre.2014.12.001","article-title":"The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology","volume":"29","author":"Yang","year":"2015","journal-title":"Blood Rev."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169398","article-title":"Citations for randomized controlled trials in sepsis literature: the halo effect caused by journal impact factor","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01100\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T04:56:10Z","timestamp":1569300970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01100\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":52,"alternative-id":["10.3389\/fphar.2019.01100"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01100","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"article-number":"1100"}}